$ News

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

BC-Most Active Stocks

MannKind to Acquire scPharmaceuticals for Up to $360 Million

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111

scPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call Transcript

scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates

scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

Cytek Biosciences, Inc. (CTKB) Beats Q2 Earnings Estimates

Shareholders in scPharmaceuticals (NASDAQ:SCPH) are in the red if they invested five years ago

scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025

scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shift From Loss To Profit

With 42% stake, scPharmaceuticals Inc. (NASDAQ:SCPH) seems to have captured institutional investors' interest

scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025

scPharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Q1 2025 scPharmaceuticals Inc Earnings Call

scPharmaceuticals Inc (SCPH) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Expansion

scPharmaceuticals Inc. (SCPH) Q1 2025 Earnings Call Transcript

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update